|January 2016:||A license agreement signed with Athersys, Inc. for the development and commercialization of novel cell therapy treatments, including MultiStem® for the treatment of ischemic stroke in Japan.|
|October 2015:||Opening of Yokohama laboratory in Yokohama City University Advanced Medical Research Center|
|June 2015:||Listed on the Tokyo Stock Exchange market Mothers (code: 4593).|
|October 2014:||Start of collaborative research with Yokohama City University on cellular and tissue-based products using iPS and other cells.|
|September 2014:||Main office was moved to Minato-ku, Tokyo.|
|February 2014:||Sighregen Co.,Ltd.., a joint venture company with Sumitomo Dainippon Pharma Co., Ltd., was established.|
|December 2013:||Agreement signed with Sumitomo Dainippon Pharma Co., Ltd. on the joint development in Japan of iPS cell–derived RPE cells for the treatment of age-related macular degeneration. A patent licensing agreement and a joint venture contract was also signed.|
Ophthalmic viscoelastic preparation business was transferred from Aqumen Biopharmaceuticals K.K.
|October 2013:||Opening of our laboratory (currently the Kobe Research Institute) in Chuo-ku, Kobe.|
|September 2013:||Business name was changed to HEALIOS K.K.|
The Tokyo office and the main office were moved to Chuo-ku, Tokyo.
|March 2013:||A patent licensing agreement was concluded with RIKEN, on RPE cells for the treatment of age-related macular degeneration.|
|February 2013:||A patent licensing agreement was concluded with iPS Academia Japan, Inc. on iPS cell basic technology related to cellular therapy products containing RPE cells as an active ingredient.|
|December 2012:||Tokyo office was opened in Chiyoda-ku, Tokyo.|
|August 2011:||Healios joins the Riken Venture system.|
|February 2011:||Retina Institute Japan, K.K. (currently HEALIOS K.K.) was established in Higashi-ku, Fukuoka City.|
Discussions were initiated on strategies to commercialize RPE cell transplantation as a treatment for age-related macular degeneration.